



## Anxiolytic and Antidepressant Effects of a Tris(2-aminoethyl)amine Derivative: A Preclinical Study

Meena Zaman<sup>1</sup>, Jalwa Ali khan<sup>1</sup>, Kainat Bibi<sup>2</sup>, Iram Alam Sthanadar<sup>3</sup>, Muhammad Saeed Jan\*<sup>1</sup>

<sup>1</sup>Department of Pharmacy, Bacha Khan University, Charsadda, KP, Pakistan.

<sup>2</sup>Women Institute of learning, Abbotabad, KP, Pakistan

<sup>3</sup>Department of Zoolog, Islamia College University, KP, Peshawar Pakistan

### Correspondence:

Dr. Muhammad Saeed Jan  
[saeedjanpharmacist@gmail.com](mailto:saeedjanpharmacist@gmail.com)

### Funding Information

Not Applicable

### Abstract

Anxiety and depression are among the most prevalent mental health disorders, affecting a vast portion of the population. Despite the well-established efficacy of first-line anxiolytic and antidepressant treatments, their significant side effects often drive individuals to seek alternative therapies. Trisamine-based drugs have drawn interest in the modern age because of their potency, efficacy, broad pharmacological activity, and decreased adverse effects. They are a safer, more effective, and more affordable option for treating mental health issues because of their promising therapeutic profile. Trisamine derivatives' neuropharmacological potential was assessed in this study, with a focus on their sedative, anxiolytic, and antidepressant properties. The chosen compound was screened using a variety of behavioral models, and the results were significant. Compound N-1 showed very less sedative activity at highest tested dose in open field test, however it demonstrated highly significant (\*\*\*)  $P < 0.001$  anxiolytic effects in behavioral assessments. Although forced swimming test (FST), compound N-1 proved some activity at highest tested dose, the activity become decreased with decrease in dose which shows it has dose dependant antidepressant activity. The selected compounds exhibited strong neuropharmacological effects.

### KEYWORDS

Trisamine compound, Anxiolytic, Antidepressant, Neuropharmacological effects.

## 1.0 INTRODUCTION

Among the most widespread psychiatric conditions, Anxiety and depression impose a heavy toll on patient well-being and global healthcare resources [1]. Current clinical guidelines prioritize pharmacological intervention, specifically selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), as primary treatments [2]. While agents like citalopram and escitalopram improve mood by modulating serotonergic pathways they are associated with certain adverse effects such as delayed onset of action, emotional blunting, and withdrawal. These drawbacks highlight the need for novel therapeutics with improved efficacy and safety [3]. Research has


increasingly focused on nitrogen-containing heterocyclic compounds due to their diverse biological activities, including neuropharmacological effects. Tris(2-aminoethyl)amine (TREN) derivatives, in particular, have gained attention due to their strong metal chelation properties [4], neuroprotective potential, and ability to modulate serotonin and GABA pathways. The heterocyclic compounds having nitrogen in their moiety are of great attention nowadays for diverse pharmacological potentials [5]. In medicinal chemistry, various TREN derivatives have shown promise in diverse therapeutic applications, including antimicrobial, anticancer, and anti-inflammatory properties [6]. However, limited research has been conducted on their potential role as

anxiolytic and antidepressant agents. Some studies indicate that modifications in TREN structures enhance their ability to interact with central nervous system (CNS) receptors, particularly those involved in monoamine regulation [7]. Recent advancements in synthetic chemistry have enabled the development of novel TREN-based compounds with improved pharmacokinetic properties. The current study aims in the development of Tris amine derivatives. Through

the development of novel anxiolytic and antidepressant compounds with improved therapeutic potential and minimal adverse effects.

## 2.0 MATERIALS AND METHODS

The compound was donated by the Institute of Chemical Sciences, University of Peshawar. The structure, molecular formula, Mass and solubility of the compounds are displayed in **Table 1**.

Sample Code	Structure of Compound	Molecular Formula	Mass	Solubility
N-1		$C_{18}H_{33}N_7S_6$	539.87	DMSO (1%)

these investigations, the study aims to contribute to

**Table 1: Chemical characteristics of the tested polyamine derivative (N-1).**

## 2.1 Experimental Animals and Treatment Regimen

BALB mice weighing 18–22 grams, both male and female, were acquired from the National Institute of Health (NIH), located in Islamabad. The test compound, Tris(2-aminoethyl)amine (TREN) derivatives, was administered via the peritoneal (p.o.) route. The doses were selected based on preliminary toxicity studies and previous literature on structurally related compounds. Intraperitoneal administration was performed using freshly prepared solutions, maintaining sterile conditions to prevent contamination. The experimental animals were divided into groups, having (n=6), which consisted of an equal number of mice of both sexes. They were administered various doses of the compound in mg/kg, adjusted according to their body weights. The tested concentration range included 5, 2.5, and 1.25 mg/kg, i.p. The control group received 1% DMSO in

normal saline/distilled water, serving as the vehicle control, while standard drug-treated groups received clinically relevant doses of fluoxetine (SSRI) and diazepam (benzodiazepine) as reference antidepressant and anxiolytic agents. Before experimentation, the animals were acclimatized to the laboratory environment under standard conditions, including a controlled temperature of 25°C and a 12/12-hour light-dark cycle to minimize stress and ensure reliable results. Doses were administered once daily at the same time each day to maintain consistency, and the duration of drug exposure varied based on the specific behavioral and biochemical assessments conducted in the study.

## 2.2 *In vivo* Studies

### 2.2.1 Acute Toxicity

To determine acute toxicity, various doses were delivered to groups of six mice of both sexes. The observation protocol consisted of an initial 2-

hour period of constant monitoring, intermittent checks for an additional 4 hours, and a final evaluation after 72 hours to record any delayed physiological responses [8-9].

**2.2.2 Sedative Activity**

For the assessment of sedative activity, the mice's crossings of squares in the apparatus were counted [10].

**2.2.3 Anxiolytic Activity**

For anxiolytic activity, the frequency of rearing behavior and the number of steps ascended were tracked for three minutes [11].

**2.2.4 Antidepressant Activity**

Similarly,for antidepressant activity, each

mouse was submerged in water and given 360 seconds to swim for 30 minutes following treatment. In order to assess depressive-like behavior, the time of immobility during the final 240 seconds of the test was recorded [12].

**2.3 STATISTICAL ANALYSIS**

All tests were performed in triplicate and values were represented as mean ± standard deviation. Results were interpreted based on concentration-dependent activity patterns [13].

**3.0 RESULTS**

**3.1 Acute toxicity result**

There was no mortality observed during the observation period, indicating that the compounds are well tolerated at various concentrations ranging from 50-1000 mg/kg body weight, as shown in **Table 2**

**Table 2 Acute Toxicity**

Compound	Dose(mg/kg)	Mortality
N-1	50	–
	100	–
	200	–
	400	–
	600	–
	800	–
	1000	–

**3.2 *In vivo* Pharmacological potential of compound N-1**

The number of lines crossed by mice when treated with the test compound **N-1** were observed to be decreased. Significant sedative activity (\*\*P< 0.001) was observed at 5 and 2.5 mg/kg, and 1.25mg/kg which shows the sedative activity of the compound at all the tested doses. Compound **N-1** showed highly significant (\*\*P< 0.001) effect across all tested doses (5, 2.5, and 1.25 mg/kg), demonstrating strong anxiolytic property. The

decreased number of steps and rearing showed that the test compound has anxiolytic potential at these tested doses. At a dose of 5 and 2.5mg/kg, demonstrated a significant (\*\*P<0.001) reduction in immobility time,however at the tested dose of 1.25mg/kg, a significance of (\*P<0.01) was noted; The statistical data indicate that this compound's antidepressant action is dose dependent. These activities are tabulated in **Table 3**.

Table 3 Sedative, Anxiolytic and Antidepressant Activity of the compound N-1

Sedative activity			
Groups	Dose(mg/kg)	Number of lines crossed by mice in 10 min	
Normal Saline	10 ml/kg	121 ± 0.56	
Diazepam	0.5 mg/kg	5.01 ± 0.67***	
N-1	5 (mg/kg)	110±1.202*	
	2.5 (mg/kg)	135.3±4.87	
	1.25 (mg/kg)	148.0±4.72	
Anxiolytic activity			
Groups	Dose (mg/kg)	Number of steps	Number of rearing
Normal Saline	10 ml/kg	23.566 ± 2.1	10.3 ± 0.32
Diazepam	0.5 (mg/kg)	2.54 ± 0.22***	1.667 ± 0.32***
N-1	5 (mg/kg)	1.333±1.52***	0.6667±1.15***
	2.5 (mg/kg)	12.00±2.00***	1.667±1.52***
	1.25 (mg/kg)	13.67±1.155***	0.333±0.54***
Antidepressant Activity			
Groups	Dose (mg/kg)	Immobility Time of Animal in Seconds	
Normal saline	10 ml/kg	100.00 ± 0.55	
Fluoxetine	0.5 (mg/kg)	25.66 ± 0.31***	
N-1	5 (mg/kg)	78.00±1.08*	
	2.5 (mg/kg)	88.33±1.33	
	1.25 (mg/kg)	108.3±2.91	

Experiments were performed in triplicate and results were represented as the mean ± standard deviation. The analysis of results focused on identifying dose-dependent activity patterns. The values were compared to the normal saline group. \*\*\*P < 0.001, \*\*P < 0.01, \*P < 0.05, P > 0.05 = ns (not significant) to that of the control group.

#### 4.0 DISCUSSION

The pharmacological evaluation of Compound N-1 reveals a promising therapeutic profile characterized by potent CNS activity and a high safety margin [14]. The absence of mortality at all the administered doses suggests that the compound is well-tolerated within the tested range. The number of lines that the animal crossed after treatment with N-1 compound were increased with decrease in dose. A ( $p < 0.05$ ), significant result was observed at 5mg/kg. The decline in number of steps was

observed to be ( $p < 0.001$ ) significant at all the tested doses, which shows anxiolytic activity of this compound.

Compound N-1 had a significance of ( $p < 0.05$ ) at test dose of 5mg/kg. It was observed the immobility time of the compound was increased at the doses of 2.5 and 1.25mg/kg, which indicates that the compound has no antidepressant effect at low doses. The size of the side chain can affect the compound's overall lipophilicity, which in turn influences its bioavailability, distribution, and

metabolism. The presence of a methyl group in a specific position may optimize interactions with the target, leading to increased potency or selectivity. The above discussion shows that this compound has non sedative anxiolytic activity.

## 5.0 CONCLUSION

This study demonstrates that compound **N-1** is a promising candidate for the treatment of anxiety and depression, exhibiting dose-dependent efficacy and a favorable safety profile. These results suggest that TREN derivatives could serve as scaffolds for a novel class of dose dependant sedative psychotherapeutic agents. Further development and optimization of these compounds may provide more effective and better-tolerated alternatives to existing treatments for depression and anxiety.

## ACKNOWLEDGEMENT

The authors are thankful to the Department of Pharmacy, University of Peshawar, for donating the compound **N-1**.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## 6.0 REFERENCES

1. Banerjee, D., et al., Impact of the COVID-19 pandemic on psychosocial health and well-being in South-Asian (World Psychiatric Association zone 16) countries: A systematic and advocacy review from the Indian Psychiatric Society. *Indian Journal of Psychiatry*, 2020. **62**(Suppl 3): p. S343-S353.
2. Qaseem, A., et al., Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians. *Annals of internal medicine*, 2023. **176**(2): p. 239-252.
3. Cipriani, A., et al., Citalopram versus other anti-depressive agents for depression. *Cochrane Database of Systematic Reviews*, 2012(7).
4. Baral, M., et al., A Novel Tris (2-aminoethyl) amine Based Tripodal Ligand: Synthesis and Solution Coordination Studies with Trivalent Iron and Chromium. *Journal of Applied Chemistry*, 2016. **2016**(1): p. 3757418.
5. Sadiq, A., et al., 3-(((1 S, 3 S)-3-((R)-Hydroxy (4-(trifluoromethyl) phenyl) methyl)-4-oxocyclohexyl) methyl) pentane-2, 4-dione: Design and Synthesis of New Stereopure Multi-Target Antidiabetic Agent. *Molecules*, 2022. **27**(10): p. 3265.
6. Alessio, E., *Bioinorganic medicinal chemistry*. 2011: John Wiley & Sons.
7. Alam, W., et al., Synthesis, in-vitro inhibition of cyclooxygenases and in silico studies of new isoxazole derivatives. *Frontiers in chemistry*, 2023. **11**: p. 1222047.
8. Jan, M.S., et al., Synthesis of pyrrolidine-2, 5-dione based anti-inflammatory drug: in vitro COX-2, 5-LOX inhibition and in vivo anti-inflammatory studies. *Latin Am J Pharm*, 2019. **38**(11): p. 2287-2294.
9. Hussain, F., et al., Screening of *Abenaria plantaginea* Lindl for anti-alzheimer potential. *Phytopharmacology Research Journal*, 2025. **4**(3): p. 101-107.
10. Akkol, E.K., et al., Sedative and anxiolytic activities of *Opuntia ficus indica* (L.) Mill.: An experimental assessment in mice. *Molecules*, 2020. **25**(8): p. 1844.
11. Seibenhener, M.L. and M.C. Wooten, Use of the open field maze to measure locomotor and anxiety-like behavior in mice. *Journal of visualized experiments: JoVE*, 2015(96): p. 52434.
12. Saviluoto, T., Chronic antidepressant administration and validation of automatized analysis of forced swim test on mice. 2022, Itä-Suomen yliopisto.
13. Ejaz, I., et al., Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2, 5-dione analogs for the treatment of breast cancer. *Bioorganic & Medicinal Chemistry Letters*, 2022. **64**: p. 128668.
14. Khan, A., et al., Phytochemical profiling, anti-inflammatory, anti-oxidant and in-silico approach of *cornus macrophylla* bioss (Bark). *Molecules*, 2022. **27**(13): p. 4081.